A business in context

QTTB research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-08 · 8005 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-08-25 · 0001193125-26-371293

  2. 4 · Ownership change

    Report date 2026-08-25 · 0001193125-26-371292

  3. 4 · Ownership change

    Report date 2026-08-25 · 0001193125-26-371291

  4. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-333831

  5. 8-K · Current report

    Report date 2026-08-05 · 0001193125-26-333813 · Items 2.02,9.01

  6. 4/A · Ownership change

    Report date 2026-06-12 · 0001193125-26-310983

  7. 4/A · Ownership change

    Report date 2026-06-12 · 0001193125-26-310982

  8. 4/A · Ownership change

    Report date 2026-06-12 · 0001193125-26-310980

  9. 4/A · Ownership change

    Report date 2026-06-12 · 0001193125-26-310978

  10. 4/A · Ownership change

    Report date 2026-06-12 · 0001193125-26-310970

  11. 8-K · Current report

    Report date 2026-07-14 · 0001193125-26-304964 · Items 1.01,9.01

  12. 8-K · Current report

    Report date 2026-07-13 · 0001193125-26-301520 · Items 8.01,9.01

  13. 8-K · Current report

    Report date 2026-07-13 · 0001193125-26-301464 · Items 7.01,8.01,9.01

  14. 8-K · Current report

    Report date 2026-06-12 · 0001193125-26-272562 · Items 5.07

  15. 8-K · Current report

    Report date 2026-05-26 · 0001193125-26-241846 · Items 1.01,3.02,8.01,9.01

  16. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-205021

  17. 8-K · Current report

    Report date 2026-05-05 · 0001193125-26-205006 · Items 2.02,9.01

  18. DEF 14A · Proxy statement

    Report date 2026-06-12 · 0001193125-26-193934

  19. 8-K · Current report

    Report date 2026-04-24 · 0001193125-26-177178 · Items 8.01,9.01

  20. 8-K · Current report

    Report date 2026-03-27 · 0001193125-26-129431 · Items 1.01,9.01

  21. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-099339

  22. 8-K · Current report

    Report date 2026-03-10 · 0001193125-26-099328 · Items 2.02,9.01

  23. 8-K · Current report

    Report date 2026-02-17 · 0001193125-26-054711 · Items 1.01,8.01,9.01

  24. 8-K · Current report

    Report date 2025-12-17 · 0001193125-25-326821 · Items 5.02

  25. 8-K · Current report

    Report date 2025-11-28 · 0001193125-25-303115 · Items 1.01,1.02,2.01,7.01,8.01,9.01

  26. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-278812

  27. 8-K · Current report

    Report date 2025-11-13 · 0001193125-25-278805 · Items 2.02,9.01

  28. 8-K · Current report

    Report date 2025-10-21 · 0001193125-25-244262 · Items 8.01,9.01

  29. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-103530

  30. 8-K · Current report

    Report date 2025-08-06 · 0000950170-25-103526 · Items 2.02,9.01

  31. 8-K · Current report

    Report date 2025-06-20 · 0001193125-25-146179 · Items 5.02,7.01,9.01

  32. 8-K · Current report

    Report date 2025-06-13 · 0001193125-25-142039 · Items 3.03,5.03,5.07,9.01

  33. 8-K · Current report

    Report date 2025-05-19 · 0001193125-25-125435 · Items 3.01

  34. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-066371

  35. 8-K · Current report

    Report date 2025-05-08 · 0000950170-25-066366 · Items 2.02,9.01

  36. DEF 14A · Proxy statement

    Report date 2025-06-13 · 0000950170-25-059558

  37. 8-K · Current report

    Report date 2025-04-25 · 0001193125-25-096703 · Items 5.02

  38. 10-K · Annual report

    Report date 2024-12-31 · 0000950170-25-036823

  39. 8-K · Current report

    Report date 2025-03-11 · 0000950170-25-036819 · Items 2.02,9.01

  40. 8-K · Current report

    Report date 2025-03-08 · 0001193125-25-050372 · Items 8.01,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 4 transaction rows4PSale: 0 transaction rows0SGrant / award: 8 transaction rows8AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

12 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-06-12
2026-06-16
LAPORTE KATHLEENA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
9810.00.0
2026-06-12
2026-06-16
Iwicki Mark TA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
9810.00.0
2026-06-12
2026-06-16
Manke IsaacA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
9810.00.0
2026-06-12
2026-06-16
TZIANABOS ARTHURA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
9810.00.0
2026-06-12
2026-06-16
GRAYZEL DAVID S.A · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
9810.00.0
2026-06-12
2026-06-16
Thistle MaryA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
9810.00.0
2026-06-12
2026-06-16
Xu DiyongA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
9810.00.0
2026-06-12
2026-06-16
Lundberg Sven AnteA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
9810.00.0
2026-05-28
2026-06-01
Xu DiyongP · Purchase
Acquired
Common Stock1250000.08.0
2026-05-28
2026-06-01
Xu DiyongP · Purchase
Acquired
Common Stock625000.08.0
2026-05-28
2026-06-01
ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCP · Purchase
Acquired
Common Stock625000.08.0
2026-05-28
2026-06-01
ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCP · Purchase
Acquired
Common Stock1250000.08.0

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001661998Q32 Bio Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names
  • Q32 Bio Inc. · former SEC name · 2024-03-27 to 2026-08-27
  • Homology Medicines, Inc. · former SEC name · 2016-01-06 to 2024-03-22

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$0$0
2023-12-31-$6.65M-$7.29M
2018-12-31$3.68M$4.90M

Bureau of Labor Statistics · retrieved 2026-09-08 · 9 selected series; gaps remain missing

Explore the CPI history ↗